AbbVie to Highlight its Innovative Pipeline to the Investment Community
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Wall St dips as rising oil prices, hawkish Fed bets pressure stocks
AbbVie (ABBV) Issues Positive Update on Rova-T as r/r SCLC Treatment
June 6, 2016 6:26 AM EDTAbbVie (NYSE: ABBV) announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), demonstrated a confirmed overall response rate (ORR) of 39 percent and clinical benefit rate (stable disease or better) of 89 percent in patients with recurrent or refractory small cell lung cancer (SCLC), identified with high expression of DLL3. Rova-T demonstrated a one-year overall survival (OS) rate of 32 percent in the recurrent/refractory second- and third-line patient population. These new data were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in... More
